Canbex said the award will further support the preclinical trials of the company’s VSN series of compounds.
The company expects to initiate Phase I trial of VSN16R, company’s lead compound, in the beginning of December 2012.
Preclinical studies have shown that VSN16R treatment reduces muscle spasms in an animal model of MS spasticity, with a far lower burden of side effects than the decades-old compounds that are currently in clinical use.
Canbex CEO Stephane Mery said they are delighted that Canbex can move their lead compound VSN16R forward towards clinical trials.